E-688

About Palleon Pharmaceuticals

Palleon Pharmaceuticals is at the forefront of glycobiology-based drug discovery, developing first-in-class therapies that degrade cell surface sialoglycans to treat cancer and autoimmune diseases. Its core technology, the EAGLE platform, fuses human sialidase enzymes with targeting antibodies to selectively remove immunosuppressive sugar molecules from diseased cells, rendering them vulnerable to immune attack. The company has advanced programs in both oncology (E-688) and immunology (E-602), supported by a strategic collaboration with Henlius. Palleon represents a private, preclinical-stage biotech targeting a significant new frontier in immuno-oncology and inflammation.

Therapeutic Areas